BioMarin Pharmaceutical Inc.
Bear Case (25th pct.)
-73.6% vs price
Base Case (Median)
-58.4% vs price
Bull Case (75th pct.)
-47.9% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $39.59 | -40.6% | High (40%) |
| PE Comparable | $8.68 | -87.0% | Medium (25%) |
| Growth Trajectory DCF | $18.48 | -72.3% | Medium (20%) |
| Graham Number | $16.69 | -75.0% | Medium (40%) |
| EV/EBITDA | $29.87 | -55.2% | Medium (20%) |
| EV/FCF | $76.43 | 14.7% | Medium (20%) |
| Earnings Power Value | $27.71 | -58.4% | Medium (50%) |
Based on 7 out of 8 methods, BMRN appears overvalued at the current price of $66.64. The base case fair value of $27.71 implies 58.4% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.